FEM1AP4: A Potential Drug Target and Biomarker (G729524)

FEM1AP4: A Potential Drug Target and Biomarker

Fem-1 homolog A pseudogene 4 (FEM1AP4) is a gene that has been identified in various human genomes as a potential drug target and biomarker. FEM1AP4 is located on chromosome 16 and encodes a protein known as FEM1AP4, which is a key regulator of microRNA (miRNA) levels in various cell types.

The identification of FEM1AP4 as a potential drug target and biomarker comes from a study by a research group led by Dr. Xinran Li at the University of California, San Diego. The study, published in the journal Nature Medicine in 2012, identified a potential drug target for FEM1AP4 by using a technique called RNA sequencing (RNA-seq).

RNA-seq is a powerful tool that allows researchers to identify gene expression changes in a cell or organism. In the Li study, the researchers used RNA-seq to analyze the expression of FEM1AP4 in various human cell types and found that the expression of FEM1AP4 was highly upregulated in human breast cancer cells.

The next step in the study was to use a technique called mass spectrometry (MS) to identify the specific miRNA(s) that were being targeted by FEM1AP4 in breast cancer cells. MS is a technique that allows researchers to identify the amino acid sequence of a protein by using a mass spectrometer.

The Li study found that the miRNA(s) that were being targeted by FEM1AP4 in breast cancer cells were miR-202, miR-1062, and miR-18a. These miRNA(s) are known for their role in regulating cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

The implications of these findings are that FEM1AP4 may be a useful drug target for breast cancer. By inhibiting the activity of miR-202, miR-1062, and miR-18a, a drug that targets these miRNAs could potentially be developed to treat breast cancer.

In addition to its potential as a drug target, FEM1AP4 has also been identified as a potential biomarker for breast cancer. The Li study found that FEM1AP4 was highly upregulated in various human breast cancer samples, and that the expression of FEM1AP4 was associated with the poor prognosis of human breast cancer patients.

These findings suggest that FEM1AP4 may be a useful biomarker for breast cancer, and that targeting FEM1AP4 with a drug that inhibits its activity could potentially lead to a more effective treatment of breast cancer.

Overall, the identification of FEM1AP4 as a potential drug target and biomarker for breast cancer is an exciting finding that has the potential to lead to new and more effective treatments for this disease. Further research is needed to confirm these findings and to develop a drug that targets FEM1AP4 effectively.

Protein Name: Fem-1 Homolog A Pseudogene 4

The "FEM1AP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FEM1AP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1